Abstract

Objective To investigate the efficacy and safety of glimepiride combined with insulin in patients with type 2 diabetes mellitus,and their effects on insulin dosage. Methods One hundred of type 2 diabetic patients treated with insulin higher than 50 U/d( insulin alone or in combination with no more than two kinds of non-insulin-secretagogue agents) were enrolled in this multi-center,open-labeled and self-controlled study. Glimepiride was added to patients for 12 weeks. Results HbA1c decreased from ( 8. 89 ± 1.77) % to (7.02 ± 0. 86) % ( decreased ( 1. 86 ± 1.43) % ). About 31 % and 50% patients obtained the target of HbA1c≤6. 5% and HbA1c < 7. 0%. Insulin dose decreased from 66. 0 U/d to 50. 0 U/d ( decreased 26.67% ). The blood glucose profile was also improved significantly. During the study period ,30 patients experienced with minor hypoglycemia for 68 times,and the incidence was 2.95/patients · year; no serious hypoglycemia was reported. Body weight and body weight index did not change. Conclusions Glimepiride combined with insulin is efficient and safe in type 2 diabetic patients, and can decrease insulin dosage, and therefore decrease the therapeutic risks of insulin. Key words: Glimepiride; Insulin; Combination therapy; Type 2 diabetes mellitus

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.